New research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used to treat obesity and type 2 diabetes, may also offer benefits for fertility in both men and women.
The findings, presented by researchers at recent scientific meetings and supported by emerging clinical evidence, indicate that the medications could improve reproductive health by addressing several conditions associated with excess body weight and metabolic disorders.
GLP-1 drugs, including commonly prescribed medications used for weight management and blood sugar control, have gained global attention for their ability to promote significant weight loss, improve insulin sensitivity and reduce inflammation.
Medical experts say these effects may also contribute to improved fertility, particularly among individuals whose reproductive challenges are linked to obesity or metabolic dysfunction.
According to the researchers, women with conditions such as polycystic ovary syndrome (PCOS), one of the leading causes of infertility, may benefit from GLP-1 therapy through improved ovulation, better hormonal balance and healthier menstrual cycles.
The studies also suggest that men taking GLP-1 medications may experience improvements in sperm quality, hormone regulation and overall reproductive function, although researchers emphasise that the evidence remains preliminary.
Scientists noted that obesity is associated with reduced fertility in both sexes, affecting hormone production, egg quality, sperm health and pregnancy outcomes.
By helping patients achieve sustained weight loss and better metabolic health, GLP-1 medications could indirectly improve the likelihood of natural conception, they said.
However, researchers cautioned that larger clinical trials are still required before the medications can be recommended specifically as fertility treatments.
They stressed that the drugs should only be used under medical supervision and that individuals planning pregnancy should consult healthcare professionals regarding the appropriate timing of treatment.
Experts also warned that while the early findings are encouraging, fertility is influenced by numerous factors, including age, genetics, underlying medical conditions and lifestyle choices.
They added that maintaining a healthy diet, engaging in regular physical activity, avoiding tobacco and excessive alcohol consumption, and managing chronic health conditions remain essential components of reproductive health.
The researchers said future studies would seek to determine whether the fertility benefits observed are primarily due to weight loss or whether GLP-1 drugs exert direct effects on reproductive organs and hormone pathways.
Medical professionals believe the emerging evidence could eventually expand the therapeutic role of GLP-1 medicines beyond diabetes and obesity management if confirmed by further research.
The findings add to a growing body of evidence highlighting the broad health benefits of GLP-1 medications, although experts emphasise that more research is needed before changes are made to current fertility treatment guidelines.
